静脉注射免疫球蛋白对自身免疫性疾病和炎症性疾病的免疫调节作用

Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.

作者信息

Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen J-P, Chamat S, Prost F, Lacroix-Desmazes S, Kavery S V, Kazatchkine M D

机构信息

INSERM U430 and Université Pierre et Marie Curie (UPMC-Paris 6), Hôpital Broussais, 96 Rue Didot, 75014, Paris, France.

出版信息

Clin Exp Med. 2005 Dec;5(4):135-40. doi: 10.1007/s10238-005-0079-y.

DOI:10.1007/s10238-005-0079-y

PMID:16362793

Abstract

Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.

摘要

静脉注射免疫球蛋白（IVIg）已用于原发性和继发性抗体缺陷的治疗超过二十年。自20世纪80年代初以来，IVIg在特发性血小板减少性紫癜、格林-巴利综合征、慢性炎症性脱髓鞘性多发性神经病、重症肌无力、皮肌炎和川崎综合征中的治疗效果已得到证实，并且可预防同种异体骨髓移植受者的移植物抗宿主病。大量其他自身免疫性和全身性炎症性疾病中也有使用IVIg的报道。在本综述中，我们讨论了IVIg在免疫病理中发挥免疫调节作用的机制。